Cas No.: | 135558-11-1 |
Chemical Name: | Lobaplatin |
Synonyms: | Platinum,[rel-(1R,2R)-1,2-cyclobutanedimethanamine-kN,kN'][(2S)-2-(hydroxy-kO)propanoato(2-)-kO]-, (SP-4-3)- (9CI);Platinum, [rel-(1R,2R)-1,2-cyclobutanedimethanamine-.kappa.N,.kappa.N'][(2S)-2-(hydroxy-.kappa.O)propanoato(2-)-.kappa.O]-, (SP-4-3)- (9CI) (CA INDEX NAME);Platinum,[rel-(1R,2R)-1,2-cyclobutanedimethanamine-kN,kN'][(2S)-2-(hydroxy-kO)propanoato(2-)-k...;d19466;Lobaplatin (D-19466);lobaplatin;Lobaplatin |
SMILES: | CC1[O-][Pt]2(NCC3C(CC3)CN2)[O-]C1=O |
Formula: | C9H18N2O3Pt |
M.Wt: | 395.31300 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | Lobaplatin (D-19466) is a diastereometric mixture of platinum(II) complexes. Lobaplatin (D-19466) shows activity for a variety of tumour types and is a promising antitumour chemotherapeutic agent[1][2]. |
References: | [1]. Cao H, et al. Lobaplatin Inhibits Prostate Cancer Proliferation and Migration Through Regulation of BCL2 and BAX. Dose Response. 2019 Jun 5;17(2):1559325819850981. [2]. McKeage MJ, et al. Lobaplatin: a new antitumour platinum drug. Expert Opin Investig Drugs. 2001 Jan;10(1):119-28. |